CAC
PACB icon

Cowen and Company’s Pacific Biosciences PACB Stock Holding History

Cowen and Company’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-84,400
Closed -$41K – 716
2022
Q3 		$41K Buy
+84,400
New +$484K ﹤0.01% 275

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cowen and Company's PACB Position: Q4 2022 in Review

Cowen and Company sold out of Pacific Biosciences (PACB) in Q4 2022, closing a stake of 84,400 shares — an estimated $41K sold.

Cowen and Company first reported a position in PACB in Q3 2022 and held it in 1 quarter. The position peaked at $41K in Q3 2022. 236 funds tracked by Wall St. Rank hold PACB as of Q4 2022.

  • Cowen and Company reported no remaining Pacific Biosciences position as of Q4 2022 after selling out during the quarter.
  • Cowen and Company sold 84,400 Pacific Biosciences shares in Q4 2022, an estimated $41K.
  • Cowen and Company first reported a position in Pacific Biosciences in Q3 2022 and held it in 1 quarter.
  • Cowen and Company's Pacific Biosciences position peaked at $41K in Q3 2022.
  • 236 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.